Pharmaceutics
Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes.
Paula Santos, Alberto Souza Sá Filho, Vicente Aprigliano, Amanda G Duarte, Natã Alegransi Ribeiro, Katia Marques Lombardo, James Oluwagbamigbe Fajemiroye, Artur Prediger Buchholz, Victor Renault Vaz, Gaspar R Chiappa
Published: 202610.3390/pharmaceutics18010069
Abstract
Background/Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exhibit neuroprotective properties in preclinical models of Alzheimer's disease (AD), reducing amyloid accumulation, neuroinflammation, and insulin resistance within the brai…
Preview only. Read the full abstract at the source